http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2016066550-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_116c851e729089df9a427027272fa290 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A01K2217-206 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A01K2217-052 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A01K2227-105 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A01K2267-03 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A01K2267-0393 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A01K67-0275 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-8509 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A01K67-027 |
| filingDate | 2015-07-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6188cb49e6dd92ac3b2419f4ae791982 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_69ba6c7ee394e607740c79a5bb7bc66d http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f6ccabdb2399ddbf0a1a98e6157b5a98 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e3e2362984fabf2e9b7ad302975a9220 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8b4cb76b9380bb75ab3052965c2b9bad http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_61b6daede7589645c3c57bef8c69c08f |
| publicationDate | 2016-03-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | US-2016066550-A1 |
| titleOfInvention | Animal Model Expressing Luciferase under Control of the Myelin Basic Protein Promoter (MBP-luci) and Use of the Model for Bioluminescence In Vivo Imaging |
| abstract | A Myelin Basic Protein-luciferase bioimaging noninvasive model to visualize and quantify demyelination and remyelination events in the CNS at transcriptional level in vivo is provided. Luciferase-expressing transgenic animals were generated with myelin basic protein (MBP) promoter coupled to firefly luciferase reporter. The MBP-luci bioimaging model provides a means to monitor myelination status and the efficacy of a remyelination modulating test compound. An advantage of bioimaging is that a subject in a longitudinal study can serve as its own control. The same subject can be tracked over a demyelination and remyelination process continuously over a period of at least 10 weeks. This model enables normalization of individual animal imaging response and provides quality data with considerably reduced variance. In addition, because cohorts of animals need not be sacrificed at different time points, reduction in the number necessary for a compound efficacy study is possible. |
| priorityDate | 2009-12-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 284.